跳至主要内容
临床试验/NCT00140231
NCT00140231已完成1 期

Role of Leptin in the Neuroendocrine and Immune Response to Fasting in Humans

Beth Israel Deaconess Medical Center1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2002年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
13
试验地点
1
主要终点
Cortisol

研究概览

简要总结

The purpose of this study will be to determine whether giving leptin (r-metHuLeptin) to a person when he or she is fasting will reverse changes in metabolism, and hormone levels, and immune function associated with fasting, which decreases leptin levels.

详细描述

Leptin is a hormone secreted by fat cells under normal conditions and acts in the brain to decrease appetite and increase energy use. Leptin levels usually go down with fasting. This study will evaluate the secretion of an investigational agent called leptin in lean and overweight individuals while fasting and investigate the potential role of leptin as a regulator of immune function and mediator of the neuroendocrine response to food deprivation in humans. Data derived from these studies will provide insights into the mechanisms underlying altered hormone levels and immune function in malnutrition and obesity and thus may provide the basis for future therapeutic interventions for obesity.

Comparison: fed state vs. fasting state vs. fasting + leptin state

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 30 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy lean women (with body mass indices [BMI] < 25 kg/m2)
  • Overweight otherwise healthy men (with BMI > 27 kg/m2)
  • Overweight otherwise healthy women (with BMI > 27 kg/m2).

排除标准

  • A history of any illness that may affect the concentrations of the hormones to be studied, e.g. infectious diseases, renal or hepatic failure, type 1 or type 2 diabetes mellitus, cancer or lymphoma, hypogonadism, malabsorption or malnourishment, hypo- or hyperthyroidism, hypercortisolism, alcoholism or drug abuse, anemia, or eating disorder
  • On medications known to affect the hormones to be measured (glucocorticoids, anti-seizure medications, and thyroid hormones)
  • A known history of anaphylaxis or anaphylactoid-like reactions, or a known hypersensitivity to E. coli derived proteins

研究组 & 干预措施

Metreleptin

Active Comparator

r-metHuLeptin self-administered subcutaneously

干预措施: r-metHuLeptin (Drug)

Metreleptin

Active Comparator

r-metHuLeptin self-administered subcutaneously

干预措施: placebo (Other)

Placebo

Placebo Comparator

Placebo, administered in same method as active arm.

干预措施: r-metHuLeptin (Drug)

Placebo

Placebo Comparator

Placebo, administered in same method as active arm.

干预措施: placebo (Other)

结局指标

主要结局

Cortisol

时间窗: four days

ACTH Mean Level

时间窗: 4 days

Response of ACTH to leptin administration in fed and fasting state from baseline was measured

Immune Function CD3 Count

时间窗: 4 days

次要结局

  • %Fat Mass(four days)
  • (RMR)(four days)
  • Autonomic Function(four days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Christos Mantzoros

Professor of Medicine

Beth Israel Deaconess Medical Center

研究点 (1)

Loading locations...

相似试验